DGIdb - YOHIMBINE Drug Record

YOHIMBINE chembl:CHEMBL15245 Approved

Alternate Names:

YOHIMBINE
17ALPHA-HYDROXYYOHIMBAN-16ALPHA-CARBOXYLIC ACID METHYL ESTER
QUEBRACHINE
ACTIBINE®
JOHIMBIN
YOHIMBIN
YOHIMBIC ACID METHYL ESTER
QUEBRACHIN
CORYNINE
(16ALPHA,17ALPHA)-17-HYDROXYYOHIMBAN-16-CARBOXYLIC ACID METHYL ESTER
APHRODINE
(+)-YOHIMBINE
chemidplus:146-48-5
chembl:CHEMBL15245
pubchem.compound:8969
rxcui:220982
drugbank:01392

Drug Info:

Drug Class	anti-impotence agents
Drug Class	mydriatics
Year of Approval	not approved by the fda
FDA Approval	not approved by the FDA
Drug Class	small molecule
Drug Indications	Anti-impotence Agents
Drug Indications	Mydriatics

(2 More Sources)

Publications:

Cleary et al., 2002, Investigation of neurotransmission in vas deferens from alpha(2A/D)-adrenoceptor knockout mice., Br. J. Pharmacol.
Rizzo et al., 2001, Postjunctional alpha(2C)-adrenoceptor contractility in human saphenous vein., Eur. J. Pharmacol.
Kalkman et al., 2003, alpha2C-Adrenoceptor blockade by clozapine and other antipsychotic drugs., Eur. J. Pharmacol.
Lalchandani et al., 2002, Yohimbine dimers exhibiting selectivity for the human alpha 2C-adrenoceptor subtype., J. Pharmacol. Exp. Ther.
Millan et al., 2000, Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states., Synapse
Cleary et al., 2005, The alpha (1D)-adrenoceptor antagonist BMY 7378 is also an alpha (2C)-adrenoceptor antagonist., Auton Autacoid Pharmacol
Zádori et al., 2007, Pre- and postsynaptic mechanisms in the clonidine- and oxymetazoline-induced inhibition of gastric motility in the rat., Neurochem. Int.
Laurila et al., 2007, The second extracellular loop of alpha2A-adrenoceptors contributes to the binding of yohimbine analogues., Br. J. Pharmacol.
Ozdoğan et al., 2006, The analgesic efficacy of partial opioid agonists is increased in mice with targeted inactivation of the alpha2A-adrenoceptor gene., Eur. J. Pharmacol.
Paul et al., 1999, Molecular mechanism of thromboxane A(2)-induced platelet aggregation. Essential role for p2t(ac) and alpha(2a) receptors., J. Biol. Chem.
Vilardaga JP et al., 2005, Molecular basis of inverse agonism in a G protein-coupled receptor., Nat Chem Biol
Gyires et al., 2000, Functional evidence that gastroprotection can be induced by activation of central alpha(2B)-adrenoceptor subtypes in the rat., Eur. J. Pharmacol.
Takada et al., 2002, Meperidine exerts agonist activity at the alpha(2B)-adrenoceptor subtype., Anesthesiology
Freitag et al., 1996, Adrenoceptor- and cholinoceptor-mediated mechanisms in the regulation of 5-hydroxytryptamine release from isolated tracheae of newborn rabbits., Br. J. Pharmacol.
Alonso et al., 2007, Yohimbine prevents morphine-induced changes of glial fibrillary acidic protein in brainstem and alpha2-adrenoceptor gene expression in hippocampus., Neurosci. Lett.
Le Corre P et al., 2004, Human sympathetic activation by alpha2-adrenergic blockade with yohimbine: Bimodal, epistatic influence of cytochrome P450-mediated drug metabolism., Clin Pharmacol Ther

YOHIMBINE ADRA2B

Interaction Score: 1.89

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
12110610 10822066 12170055 8872361 10611634 17123717

Sources:
TdgClinicalTrial TEND PharmGKB
YOHIMBINE ADRA2A

Interaction Score: 1.74

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
17664022 17558432 16325800 12591093 10506165 10611634 16407989

Sources:
DTC TdgClinicalTrial TEND PharmGKB TTD
YOHIMBINE ADRA2C

Interaction Score: 1.5

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
12110610 11226402 12591093 12438517 10611634 16176444

Sources:
TdgClinicalTrial TEND PharmGKB
YOHIMBINE DRD1

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
YOHIMBINE CYP2D6

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15289791

Sources:
PharmGKB
YOHIMBINE EHMT2

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

TEND: YOHIMBINE
- Version: 01-August-2011
Alternate Names:

YOHIMBINE Primary Drug Name

Drug Info:

Year of Approval not approved by the fda

Drug Class mydriatics

Drug Class anti-impotence agents

Publications:
TdgClinicalTrial: YOHIMBINE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications Mydriatics

Drug Indications Anti-impotence Agents

Drug Class small molecule

Publications:
DTC: YOHIMBINE
- Version: 02-September-2020
Alternate Names:

CHEMBL15245 ChEMBL Drug ID

Drug Info:

Publications:

Vilardaga JP et al., 2005, Molecular basis of inverse agonism in a G protein-coupled receptor., Nat Chem Biol

PharmGKB: yohimbine

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Le Corre P et al., 2004, Human sympathetic activation by alpha2-adrenergic blockade with yohimbine: Bimodal, epistatic influence of cytochrome P450-mediated drug metabolism., Clin Pharmacol Ther

TTD: Yohimbine
- Version: 2020.06.01
Alternate Names:

D0H4JM TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL15245
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:

Trial Name	-
Novel drug target	Established target

Trial Name	-
Novel drug target	Established target

Trial Name	-
Novel drug target	Established target

YOHIMBINE Drug Record

YOHIMBINE chembl:CHEMBL15245 Approved

Alternate Names:

Drug Info:

Publications:

YOHIMBINE ADRA2B

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info: Trial Name - Novel drug target Established target

PMIDs: 12110610 10822066 12170055 8872361 10611634 17123717

Sources: TdgClinicalTrial TEND PharmGKB

YOHIMBINE ADRA2A

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info: Trial Name - Novel drug target Established target

PMIDs: 17664022 17558432 16325800 12591093 10506165 10611634 16407989

Sources: DTC TdgClinicalTrial TEND PharmGKB TTD

YOHIMBINE ADRA2C

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info: Trial Name - Novel drug target Established target

PMIDs: 12110610 11226402 12591093 12438517 10611634 16176444

Sources: TdgClinicalTrial TEND PharmGKB

YOHIMBINE DRD1

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

YOHIMBINE CYP2D6

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15289791

Sources: PharmGKB

YOHIMBINE EHMT2

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

TEND: YOHIMBINE

Alternate Names: YOHIMBINE Primary Drug Name

Drug Info: Year of Approval not approved by the fda Drug Class mydriatics Drug Class anti-impotence agents

Publications:

TdgClinicalTrial: YOHIMBINE

Alternate Names:

Drug Info: Drug Indications Mydriatics Drug Indications Anti-impotence Agents Drug Class small molecule

Publications:

DTC: YOHIMBINE

Alternate Names: CHEMBL15245 ChEMBL Drug ID

Drug Info:

Publications: Vilardaga JP et al., 2005, Molecular basis of inverse agonism in a G protein-coupled receptor., Nat Chem Biol

PharmGKB: yohimbine

Alternate Names:

Drug Info:

Publications: Le Corre P et al., 2004, Human sympathetic activation by alpha2-adrenergic blockade with yohimbine: Bimodal, epistatic influence of cytochrome P450-mediated drug metabolism., Clin Pharmacol Ther

TTD: Yohimbine

Alternate Names: D0H4JM TTD Drug ID

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL15245

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
12110610 10822066 12170055 8872361 10611634 17123717

Sources:
TdgClinicalTrial TEND PharmGKB

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
17664022 17558432 16325800 12591093 10506165 10611634 16407989

Sources:
DTC TdgClinicalTrial TEND PharmGKB TTD

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
12110610 11226402 12591093 12438517 10611634 16176444

Sources:
TdgClinicalTrial TEND PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
15289791

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Alternate Names:

YOHIMBINE Primary Drug Name

Drug Info:

Year of Approval not approved by the fda

Drug Class mydriatics

Drug Class anti-impotence agents

Drug Info:

Drug Indications Mydriatics

Drug Indications Anti-impotence Agents

Drug Class small molecule

Alternate Names:

CHEMBL15245 ChEMBL Drug ID

Publications:

Vilardaga JP et al., 2005, Molecular basis of inverse agonism in a G protein-coupled receptor., Nat Chem Biol

Publications:

Le Corre P et al., 2004, Human sympathetic activation by alpha2-adrenergic blockade with yohimbine: Bimodal, epistatic influence of cytochrome P450-mediated drug metabolism., Clin Pharmacol Ther

Alternate Names:

D0H4JM TTD Drug ID